Skip to main content
Premium Trial:

Request an Annual Quote

Orchid Says Surge in Service Receipts Drove Q2 Revenue Growth

NEW YORK, Aug. 8 - Orchid Biosciences today reported a surge in total second-quarter revenues atop decreased R&D spending and a widened net loss.

 

For the period ended June 30, Orchid said that total revenues increased to $16.4 million from $6.7 million in the same quarter one year ago. The dramatic increase was primarily due to strong SNP and identity-genomics services, which grew in the current second quarter to $13.5 million from $4.4 million one year ago, the company said.

 

Revenue from product sales also increased to $2.3 million from $1.2 million in the second quarter 2001, while receipts from collaborations and licenses in the second quarter fell to $624,000 from $1 million, according to Orchid.

 

The company said it spent $6.2 million on R&D in the current second quarter, a decrease from the $9.2 million it posted in the same period 2001.

 

Net loss shrank to $12 million, or $.22 per share, from $14 million, or $.41 per share, in the year-ago period, Orchid said.

 

The company reported having about $24 million in cash, cash equivalents, and short-term investments and restricted cash as of June 30.

 

Click here for more information.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.